Floatz logo

cd19/cd22-car-transduced t cells

Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)Cell therapyPhase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

182 Active assets in the Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
THIOGUANINE ANHYDROUS
St. Jude Children's Research Hospital
Phase 4BBB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 4BB
ASPARAGINASE
Centre Hospitalier Universitaire de Nice
Phase 4BB
Daunorubicin
PETHEMA Foundation
Phase 4BB
VINCRISTINE SULFATE
Children's Oncology Group
Phase 3BB

View all 50 →

Same molecule, other indications

cd19/cd22-car-transduced t cells is also rated in:

B-precursor ALLDormant
CCC
Indicative ·
48 / 100
View asset →
Leukemia, Lymphocytic, B CellDormant
CCC
Indicative ·
48 / 100
View asset →
B-AllDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →